EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.

•Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) plus bevacizumab significantly improved progression-free survival and overall survival for patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastasis.•Adverse effects were acceptable and manageable, and no unexpected serious adverse effects were observed in each group.•EGFR-TKIs plus bevacizumab could be an alternative therapeutic option for those patients.